Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 90,164 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 90,164 shares of the firm’s stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $1.22, for a total transaction of $110,000.08. Following the transaction, the director directly owned 3,853,195 shares of the company’s stock, valued at $4,700,897.90. The trade was a 2.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Luke Evnin also recently made the following trade(s):

• On Thursday, November 6th, Luke Evnin sold 34,947 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.21, for a total transaction of $42,285.87.
• On Wednesday, November 5th, Luke Evnin sold 30,774 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total transaction of $37,544.28.
• On Monday, November 3rd, Luke Evnin sold 60,369 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.29, for a total transaction of $77,876.01.
• On Friday, October 31st, Luke Evnin sold 73,192 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.28, for a total transaction of $93,685.76.
• On Thursday, October 30th, Luke Evnin sold 55,795 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.43, for a total transaction of $79,786.85.
• On Wednesday, October 29th, Luke Evnin sold 86,154 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.55, for a total transaction of $133,538.70.
• On Tuesday, October 28th, Luke Evnin sold 44,327 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.64, for a total transaction of $72,696.28.
• On Monday, October 27th, Luke Evnin sold 46,664 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.72, for a total transaction of $80,262.08.

Werewolf Therapeutics Price Performance

Shares of Werewolf Therapeutics stock traded down $0.02 during mid-day trading on Thursday, reaching $1.20. 647,728 shares of the stock were exchanged, compared to its average volume of 891,846. The company has a market cap of $58.25 million, a price-to-earnings ratio of -0.74 and a beta of 0.72. The company has a current ratio of 3.87, a quick ratio of 5.30 and a debt-to-equity ratio of 0.73. The firm has a 50-day simple moving average of $1.61 and a 200 day simple moving average of $1.32. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.60 and a fifty-two week high of $2.41.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. On average, sell-side analysts predict that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

Several institutional investors have recently modified their holdings of HOWL. Jane Street Group LLC acquired a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth approximately $409,000. Marshall Wace LLP acquired a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth approximately $113,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth approximately $92,000. AQR Capital Management LLC acquired a new stake in shares of Werewolf Therapeutics during the 1st quarter worth approximately $79,000. Finally, Nuveen LLC acquired a new stake in shares of Werewolf Therapeutics during the 1st quarter worth approximately $71,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. JMP Securities dropped their target price on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. Citigroup reiterated a “buy” rating on shares of Werewolf Therapeutics in a research report on Monday, August 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Zacks Research upgraded shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 16th. Finally, Bank of America lowered their price objective on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, August 25th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.